Published in Obes Res on April 01, 2004
Gastrointestinal regulation of food intake. J Clin Invest (2007) 4.47
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism (2011) 1.41
Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci (2006) 1.27
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol (2010) 0.97
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag (2008) 0.94
Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther (2008) 0.89
Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol Behav (2010) 0.89
GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol (2012) 0.87
Leptin does not directly regulate the pancreatic hormones amylin and pancreatic polypeptide: interventional studies in humans. Diabetes Care (2008) 0.82
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag (2006) 0.82
Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med (2010) 0.82
Bariatric embolization of the gastric arteries for the treatment of obesity. J Vasc Interv Radiol (2015) 0.81
Amylin-mediated control of glycemia, energy balance, and cognition. Physiol Behav (2016) 0.78
Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol (2006) 0.77
Tackling obesity: new therapeutic agents for assisted weight loss. Diabetes Metab Syndr Obes (2010) 0.76
Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med Chem J (2011) 0.76
Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs (2011) 0.76
Disaggregation of Amylin Aggregate by Novel Conformationally Restricted Aminobenzoic Acid containing α/β and α/γ Hybrid Peptidomimetics. Sci Rep (2017) 0.75
Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model. J Diabetes Sci Technol (2010) 0.75
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. Clin Med Ther (2009) 0.75
Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure. Int J Obes Suppl (2016) 0.75
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet (2012) 3.48
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A (2008) 2.73
High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes (2002) 2.36
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care (2007) 2.14
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept (2008) 1.97
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm (2005) 1.96
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care (2002) 1.91
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther (2002) 1.64
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) (2009) 1.51
Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia. J Cereb Blood Flow Metab (2002) 1.48
Incretin-based therapies. J Diabetes (2012) 1.48
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes (2004) 1.37
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care (2003) 1.30
Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract (2011) 1.23
Assessing risk factors for obesity between childhood and adolescence: I. Birth weight, childhood adiposity, parental obesity, insulin, and leptin. Pediatrics (2002) 1.23
Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology (2008) 1.23
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol (2011) 1.21
Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol (2005) 1.19
Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol (2003) 1.16
Assessing risk factors for obesity between childhood and adolescence: II. Energy metabolism and physical activity. Pediatrics (2002) 1.14
Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr (2008) 1.12
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab (2007) 1.11
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab (2007) 1.09
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care (2003) 1.08
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther (2005) 1.07
Dimeric structure of the Oxytricha nova telomere end-binding protein alpha-subunit bound to ssDNA. Nat Struct Biol (2002) 1.04
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther (2005) 1.01
Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity (Silver Spring) (2009) 0.98
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev (2006) 0.98
Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology (2007) 0.98
Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol (2008) 0.97
Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care (2008) 0.94
Plasma adiponectin and endogenous glucose production in humans. Diabetes Care (2003) 0.93
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther (2007) 0.90
Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity (Silver Spring) (2007) 0.89
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev (2004) 0.89
Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes (2002) 0.88
Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev (2008) 0.87
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care (2005) 0.86
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol (2013) 0.86
Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians. Diabetes (2004) 0.85
Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res (2002) 0.85
Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm (2005) 0.85
Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion. Curr Diab Rep (2002) 0.85
Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight. Metabolism (2004) 0.84
Pancreatic polypeptide is involved in the regulation of body weight in pima Indian male subjects. Diabetes (2004) 0.83
Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med (2013) 0.81
It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med (2009) 0.81
Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab (2007) 0.79
Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism (2004) 0.78
Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord (2002) 0.76
Relation between physical activity and obesity. Am J Clin Nutr (2003) 0.75
Effect of cortisol on muscle sympathetic nerve activity in Pima Indians and Caucasians. J Clin Endocrinol Metab (2003) 0.75